Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna COVID-19 vaccines by Quarter
COVID-19 vaccines (Spikevax / mRNA-1273 & mNEXSPIKE / mRNA-1283) — Net product sales ($M) ($M)
Moderna COVID-19 vaccines: $91M in Q2 2026, down 20.2% from a year earlier.
Latest, Q2 2026
91
Period ended Jun 30, 2026
Change on a year earlier
-20.2%
114 in Q2 2025
History
12 quarters
Since Q3 2023
Sources
7
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Revenue Disaggregation).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 vaccines (Spikevax / mRNA-1273 & mNEXSPIKE / mRNA-1283) — Net product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 91 | -20.2% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 345 | +310.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 642 | -30.4% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 971 | -46.4% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 114 | -38.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 84 | -49.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 923 | -67.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,810 | +3.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 184 | – | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 167 | – | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,793 | – | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,757 | – | Form 10-Q (filed 2024-11-07) ↗ |
Breakdown
What makes up COVID-19 vaccines
Cite this data
StockData. (2026). Moderna COVID-19 vaccines ($M), quarterly Q3 2023–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-covid19
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.